More recently, the role of SLPIs in the pathogenesis of asthma has been elucidated in a study, in which sensitized, SLPI-deficient mice were treated with resiquimod, an immune response-modifier from the family of imidazoquinolinamines, known to inhibit allergen-induced Th2 responses [89], [90]. The gene discussed is SLPI; the disease is asthma.